Cargando…

Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma

BACKGROUND: The incidence of stage I and stage II lung adenocarcinoma (LUAD) is likely to increase with the introduction of annual screening programs for high-risk individuals. We aimed to identify a reliable prognostic signature with immune-related genes that can predict prognosis and help making i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Pancheng, Zheng, Yi, Wang, Yanyu, Wang, Yadong, Liang, Naixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542703/ https://www.ncbi.nlm.nih.gov/pubmed/33028329 http://dx.doi.org/10.1186/s12967-020-02545-z

Ejemplares similares

Expression and prognostic analyses of ITGA11, ITGB4 and ITGB8 in human non-small cell lung cancer
por: Wu, Pancheng, et al.
Publicado: (2019)

A robust prognostic gene expression signature for early stage lung adenocarcinoma
por: Krzystanek, Marcin, et al.
Publicado: (2016)

Development and Validation of a Robust Ferroptosis-Related Prognostic Signature in Lung Adenocarcinoma
por: Zhang, Anran, et al.
Publicado: (2021)

Development and validation of an immune‐related prognostic signature in lung adenocarcinoma
por: Sun, Sijin, et al.
Publicado: (2020)

Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer
por: Yang, Huaxia, et al.
Publicado: (2021)

Development and validation of a combined ferroptosis and immune prognostic signature for lung adenocarcinoma
por: Li, Han, et al.
Publicado: (2022)

Identification and Validation of Immune-Related LncRNA Prognostic Signature for Lung Adenocarcinoma
por: Wu, Guomin, et al.
Publicado: (2021)

An individualized immune prognostic signature in lung adenocarcinoma
por: Sun, Liangdong, et al.
Publicado: (2020)

Identification and Validation of a GPX4-Related Immune Prognostic Signature for Lung Adenocarcinoma
por: Feng, Zhenxing, et al.
Publicado: (2022)

Identification of four differentially methylated genes as prognostic signatures for stage I lung adenocarcinoma
por: Luo, Wei-Ming, et al.
Publicado: (2018)

Identification of cuproptosis and immune-related gene prognostic signature in lung adenocarcinoma
por: Zhang, Wentao, et al.
Publicado: (2023)

A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer
por: He, Ru, et al.
Publicado: (2019)

Identification of an Individualized Metabolism Prognostic Signature and Related Therapy Regimens in Early Stage Lung Adenocarcinoma
por: Hu, Junjie, et al.
Publicado: (2021)

Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma
por: Gao, Shugeng, et al.
Publicado: (2021)

Identification of an Innate Immune-Related Prognostic Signature in Early-Stage Lung Squamous Cell Carcinoma
por: Li, Liang, et al.
Publicado: (2021)

Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer
por: Huo, Junyu, et al.
Publicado: (2021)

Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma
por: Wang, Pengli, et al.
Publicado: (2022)

Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
por: Chen, Dung-Tsa, et al.
Publicado: (2015)

Development and validation of an immune-related gene prognostic model for stomach adenocarcinoma
por: Wu, Ming, et al.
Publicado: (2020)

Construction and validation of a novel ferroptosis-related prognostic signature for lung adenocarcinoma
por: Yang, Li, et al.
Publicado: (2023)

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma
por: Yang, Tao, et al.
Publicado: (2021)

Development and Validation of a Prognostic Gene-Expression Signature for Lung Adenocarcinoma
por: Park, Yun-Yong, et al.
Publicado: (2012)

m7G-Associated subtypes, tumor microenvironment, and validation of prognostic signature in lung adenocarcinoma
por: Wang, Guangyao, et al.
Publicado: (2022)

Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma
por: Xu, Miaorong, et al.
Publicado: (2022)

Comprehensive genomic profiling aids in understanding the lesion origins of a patient with six synchronous invasive lung adenocarcinomas: a case study
por: Song, Yang, et al.
Publicado: (2020)

Clinical Significance and Immune Landscape of Recurrence-Associated Ferroptosis Signature in Early-Stage Lung Adenocarcinoma
por: Yi, Lilan, et al.
Publicado: (2022)

Identification of an Immune Classification and Prognostic Genes for Lung Adenocarcinoma Based on Immune Cell Signatures
por: Deng, Lili, et al.
Publicado: (2022)

Establishment and validation of an eight-gene metabolic–related prognostic signature model for lung adenocarcinoma
por: Ma, Weishuang, et al.
Publicado: (2021)

Development and Validation of a Prognostic N6-Methyladenosine-Related Immune Gene Signature for Lung Adenocarcinoma
por: Zhang, Lemeng, et al.
Publicado: (2021)

Development and Validation of a 12-Gene Immune Relevant Prognostic Signature for Lung Adenocarcinoma Through Machine Learning Strategies
por: Xue, Liang, et al.
Publicado: (2020)

Construction and validation of a robust ferroptosis-associated gene signature predictive of prognosis in lung adenocarcinoma
por: Zhou, Mi, et al.
Publicado: (2022)

Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma
por: Wang, Haiqiang, et al.
Publicado: (2022)

Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma
por: Guo, Wei, et al.
Publicado: (2022)

Systematic construction and validation of an immune prognostic model for lung adenocarcinoma
por: Luo, Chenghan, et al.
Publicado: (2019)

Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism‐related genes
por: Wang, Zhihao, et al.
Publicado: (2021)

The Prognostic Model and Drug Sensitivity of LKB1-Mutant Lung Adenocarcinoma Based on Immune Landscape
por: Wang, Guanghui, et al.
Publicado: (2022)

An integrated analysis of prognostic mRNA signature in early- and progressive-stage gastric adenocarcinoma
por: Hong, Xiaoling, et al.
Publicado: (2023)

Immune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma
por: Peng, Xinyi, et al.
Publicado: (2023)

LHX3 is an early stage and radiosensitivity prognostic biomarker in lung adenocarcinoma
por: Lin, Xin, et al.
Publicado: (2017)

Development and validation of a m(6)A -regulated prognostic signature in lung adenocarcinoma
por: Chen, Yaxin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_up892t3c5dom9pjs2st04j3f7h